Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Medtronic, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Medtronic, Inc.

Regulatory records
38
Linked recall entries
4
Headquarters
Not reported
Brand website
medtronic.com
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 38 FDA records to the applicant name Medtronic, Inc.. The collection includes 2 510(k) clearances. It includes 11 original PMA approvals. 6 entries are PMA supplements. 19 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Mar 14, 1988 to Nov 8, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MHY appears in 6 of the 38 linked filings. The collection spans 13 FDA product codes and 11 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P960009, with 6 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 29 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 7000 Central Ave., NE, Minneapolis, MN, 55432. Recorded on P960009/S545, decision dated Nov 8, 2026.

Changes described in PMA records

P960009/S545: Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (B32000)

FDA approved a supplement to PMA P960009, not a new whole-system approval. The record ties S545 to the Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (B32000), and the stated change is limited to a size change for the lead insertion tool.

The decision text also names a change in tip width dimension verification testing, but it does not supply the original measurement, the revised measurement, or any clinical rationale. The supplement type is listed as Real-Time Process, with a Process Change - Manufacturer/Sterilizer/Packager/Supplier reason.

FDA approval-order wording

approval for dimensions size change for lead insertion tool and modification to tip width dimension verification testing.

Nov 8, 2026 · Real-Time Process

P130021/S188: Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti

FDA lists this action as a 30-Day Notice supplement to PMA P130021/S188 for Medtronic’s Evolut FX delivery catheter system within the Evolut FX transcatheter aortic valve system. The database record frames it as a process change, not a new PMA and not a new approval of the whole system.

The only changed item described in the supplied text is “the introduction of an automated vision system for the detection of flash.” The record does not say what “flash” refers to, where the vision system is used in the manufacturing chain, or whether any device design, indication, or clinical evidence changed.

FDA approval-order wording

the introduction of an automated vision system for the detection of flash

Nov 7, 2026 · 30-Day Notice

P960009/S548: Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense

The FDA recorded a 30-Day Notice decision coded OK30 on 2026-10-30 for P960009/S548, a supplement to Medtronic, Inc.'s Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense. The device category is an implanted electrical stimulator for parkinsonian tremor, classified under product code MHY in the Neurology specialty. The supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier.

The recorded scope covers three manufacturing changes: adding a new surface mount technology production line, revising the SMT process sequence so automated optical inspection follows each SMT assembly stage, and adding an equivalent solder paste inspection system plus a qualified de-paneling machine for PCBA production. This action concerns production process and equipment only; it is not an approval of the whole system, and no clinical, efficacy or labeling conclusions follow from the record. The source lists no documents, so inspection criteria, validation data and line qualification details remain unknown.

FDA approval-order wording

approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production

Oct 30, 2026 · 30-Day Notice

P860004/S465: SynchroMed Infusion System, Ascenda Intrathecal Catheters

FDA lists this as supplement P860004/S465 to the SynchroMed Infusion System, Ascenda Intrathecal Catheters PMA. The decision is a 30-Day Notice for a process change, so the record describes manufacturing changes tied to the existing approved system rather than a new approval of the whole device.

The specific changes are a new surface mount technology production line, a revised SMT process sequence with automated optical inspection after each SMT assembly stage, and added solder paste inspection plus a qualified de-paneling machine for PCBA production. The source does not provide clinical data, a new indication, or device performance results; it only states the manufacturing scope of the notice.

FDA approval-order wording

approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production

Oct 30, 2026 · 30-Day Notice

P960009/S547: Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (DBS Neurostimulator Implantable B35200)

The FDA recorded decision OK30 on 2026-10-29 for PMA supplement P960009/S547, a 30-Day Notice submitted by Medtronic, Inc. under the supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The supplement concerns the Activa Deep Brain Stimulation Therapy System, specifically the Percept PC BrainSense DBS Neurostimulator Implantable B35200, a device in the implanted electrical stimulator category for parkinsonian tremor (product code MHY, Neurology). The action covers the listed manufacturing process changes rather than a new approval of the whole system.

The recorded statement lists six changes: enhanced operator verification of the FactoryWorks processing step and recorded battery pre-weight; pre-weight and post-weight out-of-control action plans added to Process Operation Descriptions; software and Human Machine Interface updates that automatically reject batteries with fill weights above the established final-fill reasonable limit; dedicated white work-in-progress trays for electrolyte-filled batteries; an isopropyl alcohol wipe to remove residual electrolyte before subsequent processing; and removal of Ball Press and Button Press certification prerequisites from the ram-change procedure for Medium Rate Line 2 operators, with supervisors and engineers retaining certification responsibility. No supporting documents were included, so the basis for OK30 and any clinical implications remain unknown.

FDA approval-order wording

1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification

Oct 29, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 4 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 4 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Source information

Source updated Nov 11, 2026. Retrieved Nov 19, 2026.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementNov 8, 2026FDA
Medtronic, Inc.PMA supplementNov 7, 2026FDA
Medtronic, Inc.PMA supplementOct 30, 2026FDA
Medtronic, Inc.PMA supplementOct 30, 2026FDA
Medtronic, Inc.PMA supplementOct 29, 2026FDA
Medtronic, Inc.PMA supplementOct 29, 2026FDA
Medtronic, Inc.PMA supplementOct 29, 2026FDA
Medtronic, Inc.510(k) clearanceOct 29, 2026FDA
Medtronic, Inc.PMA supplementOct 29, 2026FDA
Medtronic, Inc.PMA supplementOct 27, 2026FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA
Medtronic, Inc.PMA supplementOct 16, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA
Medtronic, Inc.PMA supplementOct 6, 2026FDA
Medtronic, Inc.PMA supplementOct 6, 2026FDA
Medtronic, Inc.PMA supplementOct 5, 2026FDA
Medtronic, Inc.PMA supplementOct 5, 2026FDA
Medtronic, Inc.PMA supplementOct 2, 2026FDA
Harmony TPV SystemP200046/S052
Medtronic, Inc.PMA supplementSep 30, 2026FDA
Medtronic, Inc.PMA supplementSep 24, 2026FDA
Medtronic, Inc.PMA supplementSep 24, 2026FDA
Medtronic, Inc.510(k) clearanceSep 17, 2026FDA
Medtronic, Inc.PMA supplementSep 10, 2026FDA
Medtronic, Inc.PMA supplementSep 8, 2026FDA
Medtronic, Inc.PMA approvalApr 22, 2025FDA
Medtronic, Inc.PMA approvalOct 24, 2024FDA
Medtronic, Inc.PMA approvalNov 17, 2023FDA
Medtronic, Inc.PMA approvalMar 26, 2021FDA
Medtronic, Inc.PMA approvalApr 6, 2016FDA
Medtronic, Inc.PMA approvalDec 30, 2014FDA
Medtronic, Inc.PMA approvalJan 17, 2014FDA
Medtronic, Inc.PMA approvalAug 28, 2001FDA
Medtronic, Inc.PMA approvalJan 29, 1999FDA
Medtronic, Inc.PMA approvalJul 31, 1997FDA
Medtronic, Inc.PMA approvalMar 14, 1988FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.